SLRX

Salarius Pharmaceuticals, Inc.

3.50 USD
+0.98 (+38.89%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Salarius Pharmaceuticals, Inc. stock is down -7.65% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 14 June’s closed higher than May.

About Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company is headquartered in Houston, Texas.